Two companies which added Donald Trump Jr. to their board or advisory board subsequently received benefits from his father’s administration, and a third company that added him to their board may stand to benefit from a new Trump healthcare program. These three companies–Unusual Machines, Credova and BlinkRx–each added Trump’s eldest son to their boards after the 2024 presidential election, part of a flurry of new positions for the president’s eldest sons.

Don Jr. and Eric Trump have joined a total of ten companies’ boards since the 2024 election. The sudden burst of business opportunities is conspicuous, given that, prior to their father’s victory, there was no evidence that they had been such highly sought-after business leaders, outside the constellation of Trump family companies. Those positions, and the appearance they give the companies of an edge with the Trump administration, represent potential conflicts of interest that risk corrupting important functions of the executive branch, in favor of further enriching the Trump family. 

Just weeks after the 2024 election, drone maker Unusual Machines announced that Don Jr. joined its newly-created advisory board, immediately causing shares to soar. As compensation for his role on the advisory board, Don Jr. was given 200,000 shares of Unusual Machines stock. 

Don Jr.’s advisory agreement appears to have expired automatically after one year, but not before the company established itself as a supplier for the U.S. Army. In October 2025, Unusual Machines announced an order from the Army for 3,500 drone motors and other components, reportedly the company’s largest government order to date. The announcement also stated that the Army has plans to order 20,000 more components from Unusual Machines in 2026. 

In describing Don Jr.’s role with Unusual Machines, CEO Allan Evans said, “[j]ust lending some of that association has created more credibility to rise above the noise. It’d almost be like Oprah joining the WeightWatchers board, right? What does Oprah need to do? Not a lot.”

In December 2024, Don Jr. joined the board of the e-commerce and payments company PublicSquare. In August 2025, the company announced that the Consumer Financial Protection Bureau had closed its years-long investigation into Credova Financial, a wholly-owned subsidiary of PublicSquare. In a letter to PublicSquare, a CFPB official wrote that the investigation “exemplifies the type of weaponization against disfavored industries and individuals that President Trump and Acting Director Vought are committed to ending.” Credova had reportedly been the subject of consumer complaints and was accused of violating state consumer protection laws. In 2024, Don Jr. was compensated more than $3.1 million by Credova’s parent company, and Credova also currently provides “Shoot Now Pay Later” financing for the Don Jr.-backed online gun retailer, GrabAGun.

In February 2025, Don Jr. was named to the board of digital pharmacy company BlinkRx. In late July, President Trump sent letters to drug manufacturers directing them to offer direct-to-consumer sales of certain drugs within 60 days. One week later, BlinkRx launched a program that would allow pharmaceutical companies to rapidly create platforms to do just that. In September, President Trump announced TrumpRx, a government website planned to launch in 2026 that would steer consumers to purchase prescription drugs directly from manufacturers. A BlinkRx representative reportedly “told one drug company that BlinkRx could be involved with running the site on behalf of the Centers for Medicare and Medicaid Services.” 

BlinkRx was also set to host the “Future of Pharmaceuticals” summit in December which was expected to bring together pharmaceutical companies and government officials including members of the cabinet. The investment firm 1789 Capital, where Don Jr. is a partner, was a co-host of the summit, which was scheduled to end with a dinner at the Executive Branch, a private members club that Don Jr. cofounded. 1789 Capital led investment in a $140 million funding round for the company in 2024. 

In response to these events, Democratic health committee leaders in the House and Senate sent a letter to BlinkRx raising questions about potential coordination between the administration and the company. BlinkRx responded in a letter that the company first learned about TrumpRx “from press reports” and had “no role in the development” of the announcement.

Between 2020 and the 2024 election, Donald Trump Jr. was named to the board of only one company–Trump Media & Technology Group in 2022. Since the election, Don Jr. has been named to the boards of four companies–PublicSquare, GrabAGun, BlinkRx and Colombier Acquisition Corp. III–and has joined the advisory boards of four others–Unusual Machines, Polymarket, Dominari Holdings and New America Acquisition I Corp. The prediction market Kalshi and the technology-focused Mixed Martial Arts Group have both added Don Jr. as a strategic advisor. Meanwhile, Eric Trump has joined the advisory boards of Dominari Holdings and New America, and became a Strategic Board Advisor for Japanese Bitcoin treasury company Metaplanet.

The companies’ additions of the Trump brothers raise concerns about conflicts of interest. While CREW’s research did not find evidence of a clear quid pro quo, even the appearance of preferential treatment undermines public confidence in government decision-making. The Trump family’s increasingly sprawling business interests jeopardize public trust in executive branch functions like awarding government contracts and carrying out investigations.

Photo of Eric Trump and Donald Trump, Jr. by Gage Skidmore under Creative Commons license

Read More in Reports